Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

358
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
358
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

Nature reviews. Urology·2026
Same author

Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

Cancer research·2026
Same author

Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO.

JCO precision oncology·2026
Same author

Transferrin Receptor Overexpression in Solid Tumors Is Associated with Inflamed Microenvironments and Upregulated Immune Checkpoints, with Implications for Immunotherapy Sensitivity.

Cancers·2026
Same author

Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.

BJU international·2026
Same author

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Molecular cancer research : MCR·2026

Related Experiment Video

Updated: Jun 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.

Matthew C Dallos1,2, Aleksandar Z Obradovic3,4, Patrick McCann1

  • 1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 13, 2024
PubMed
Summary

Androgen deprivation therapy (ADT) rapidly alters the prostate tumor microenvironment, increasing immune cells like CD8 T cells and M1 macrophages. Understanding ADT

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.5K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.1K

Related Experiment Videos

Last Updated: Jun 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.5K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.1K

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer.
  • Emerging evidence indicates ADT influences the tumor immune microenvironment.
  • Precise understanding of ADT's immunologic timing and effects is lacking.

Purpose of the Study:

  • To investigate the immunologic shifts within the prostate tumor microenvironment during ADT.
  • To analyze the impact of degarelix (a form of ADT) on immune cell phenotypes at different time points before surgery.

Main Methods:

  • Analysis of 49 primary prostate cancers.
  • Comparison of tumors treated with degarelix (4, 7, 14 days prior to surgery) versus untreated tumors.
  • Utilized next-generation DNA/RNA sequencing and multiplexed immunofluorescence.

Main Results:

  • ADT rapidly induced an inflamed tumor microenvironment within days.
  • Observed increased activated CD8 T cells, regulatory T cells (Tregs), and M1-like macrophages.
  • Tumor cells showed upregulated MHC class I/II antigen presentation and decreased CD47 ('do not eat me' signal).

Conclusions:

  • The timing of ADT is critical for optimizing combination therapies with immune modulators.
  • The neoadjuvant presurgical setting may be ideal for such combined treatments.
  • Further prospective validation of these findings is warranted.